Synovial Sarcoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

An uncommon, aggressive soft tissue sarcoma is synovial sarcoma. However, as the tumor develops, those who are affected might feel a lump or swelling. Sometimes, a tumor's compression of a nearby nerve can reduce motion, result in numbness and/or pain, or all three. Young adults (15 to 40 years old) are typically affected by synovial sarcoma. M: F=1, 2:1, suggesting a possible slight trend in males. They make up 2-10% of all soft tissue sarcomas. Synovial sarcoma is thought to occur in 2 points out of 100,000 people. Synovial sarcoma, also referred to as synovial cell sarcoma, may be surgically treated in a way that could save a patient's life. It is somewhat contraindicated to treat these patients in primary care settings.

Description

A rare and aggressive soft tissue sarcoma is synovial sarcoma. However, as the tumor spreads, those who are affected might feel a lump or swelling. Sometimes, a tumor's compression of a nearby nerve can reduce motion, result in numbness and/or pain, or all three. Genetic factors are thought to contribute to the onset of synovial sarcoma, despite the fact that the exact cause of the condition is still unknown. These tumors frequently have X and 18 chromosome translocations in their cells. Synovial sarcoma is diagnosed most frequently using this translocation, which is specific to the disease. Adults who have synovial sarcoma, a rare cancer, often notice that it has a propensity to grow close to large joints, particularly the knees. This is typically the first indication of a deep tumor and may hurt or feel tender. Typically, synovial sarcomas grow slowly. Young children can develop these tumors, but people between the ages of 15 and 40 tend to develop them more frequently. It can take years to reach a firm diagnosis of synovial sarcoma because it typically grows slowly. Synovial sarcoma can occasionally be misdiagnosed as bursitis or arthritis. A t(X;18) chromosomal translocation and the resulting tumor gene SS18:SSX fusion define the distinctive genomic signature of synovial sarcoma. Similar to other STDs, a diagnosis can be made by combining a history, physical exam, MRI, biopsy, subsequent pathology, immunohistochemistry, and molecular testing. A worse prognosis for local disease recurrence and metastasis has been demonstrated to be associated with increased size, age, and tumor grade.

Synovial Sarcoma (Epidemiology)

Young adults (15 to 40 years old) are typically affected by synovial sarcoma. Males may be showing a slight trend (M: F=1, 2:1). They make up 2.5-10% of all soft tissue sarcomas. Synovial sarcoma is thought to affect 2.75 out of every 100,000 people. The lower extremities are typically affected. This tumor makes up roughly 5-10% of all soft tissue tumors, with 800 new cases reported annually in the United States. The third most prevalent soft tissue cancer in adolescents and young adults is synovial sarcoma. A poorly differentiated soft tissue sarcoma (STS) that is relatively uncommon is called synovial sarcoma. It is the cause of 5-10% of STDs. The age-adjusted incidence of synovial sarcoma is 0.81/1,000,000 in children and 1.42/1,000,000 in adults in the US. The median age at diagnosis for synovial sarcoma is 39 years. Compared to other STDs, it starts earlier, affects both sexes equally, and is most prevalent in adolescents and young adults. The majority of synovial sarcomas diagnosed in children (about 30%) are non-rhabdoid STDs of the non-rhabdoid subtype.

Synovial Sarcoma -Current Market Size & Forecast Trends

The market for synovial sarcoma treatment is expected to grow steadily, with the global market size valued at approximately USD 822.74 million in 2023 and projected to reach around USD 1,144.84 million by 2033, reflecting a compound annual growth rate (CAGR) of 3.6%. The market is primarily driven by the increasing incidence of synovial sarcoma, advancements in treatment options, and rising awareness about the disease. Surgery remains the dominant treatment approach, capturing a significant market share. North America is expected to hold the largest market share due to higher diagnosis rates and substantial investments in healthcare and research. Additionally, the Asia-Pacific region is anticipated to see steady growth as healthcare infrastructure improves and awareness increases. Overall, the synovial sarcoma treatment market is well-positioned for growth through 2035 as new therapies and innovative treatment strategies continue to emerge.

The surgical removal of synovial sarcoma, also known as synovial cell sarcoma, may be life-saving if there are no contraindications. There are some relative contraindications to treating these patients in primary care settings. SS is relatively chemically sensitive in comparison to other STDs. Ifosfamide alone and in combination are effective in various therapeutic modalities. Neoadjuvant doxorubicin and ifosfamide exhibited comparable activity to high-dose ifosfamide in STS of the chest wall and extremities at high risk. There are signs that chemotherapy administered in this case with doxorubicin and ifosfamide may lead to better results. For patients who are eligible, doxorubicin and ifosfamide combination therapy is advised for first-line metastatic disease, while sequential doxorubicin and ifosfamide may be considered for other patients. Second- and last-line activity was present in pazopanib and trabectedin. Other receptor tyrosine kinase inhibitors, epigenetic modulators, substances that block the DNA damage response (DDR), and immunotherapies are all being tested for the treatment of SS metastases in preclinical and clinical trials right now. Chemotherapy in the adjuvant setting is not the standard of care for adults with localized STS at any site because numerous trials of adjuvant STS, including SS, have ultimately failed to show a survival benefit. Neoadjuvant chemotherapy may be used as induction therapy to improve surgical outcomes in some circumstances, such as high-risk extremity and chest wall sarcomas. Recent data indicates that this strategy may also be advantageous for DFS. Doxorubicin, which has response rates of 16 to 27% and a median survival of about one year in ongoing clinical trials, is still regarded as the preferred first-line systemic treatment for STS. First-line systemic therapy began 18 months ago. In SS, ifosfamide is the first- or second-line treatment for the majority of eligible patients due to its known activity in SS. If the patient is ineligible for or has already received ifosfamide and doxorubicin, other options include pazopanib and trabectedin. If there is a sufficient amount of time between the conclusion of first-line combination therapy and the beginning of second-line therapy, ifosfamide monotherapy may occasionally be considered after first-line combination therapy.

Report Highlights

Synovial Sarcoma - Current Market Trends

Synovial Sarcoma - Current & Forecasted Cases across the G8 Countries

Synovial Sarcoma - Market Opportunities and Sales Potential for Agents

Synovial Sarcoma - Patient-based Market Forecast to 2035

Synovial Sarcoma - Untapped Business Opportunities

Synovial Sarcoma - Product Positioning Vis-a-vis Competitors' Products

Synovial Sarcoma - KOLs Insight